Disease · MONDO_0002529

skin squamous cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. skin squamous cell carcinoma. Diseases, record MONDO_0002529. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002529

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: skin squamous cell carcinoma; Open Targets
Open Targets ID: MONDO_0002529; Open Targets
Other names: cutaneous squamous cell carcinoma, epidermoid carcinoma of skin, epidermoid carcinoma of the skin, epidermoid skin carcinoma, skin squamous cell cancer, squamous cell carcinoma - skin, squamous cell carcinoma of skin, squamous cell carcinoma of the skin, squamous cell skin carcinoma, zone of skin squamous cell carcinoma; Open Targets
Disease Ontology: DOID:3151; Disease Ontology
NCI Thesaurus: C4819; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 12 of its 20 drugs, from ClinicalTrials.gov; Open Targets

Drugs20

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CETUXIMAB	CHEMBL1201577	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GEFITINIB	CHEMBL939	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DACOMITINIB ANHYDROUS	CHEMBL2110732	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
NOVAFERON	CHEMBL4650410		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
PEGINTERFERON ALFA-2B	CHEMBL1201561	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RIGOSERTIB	CHEMBL1241855	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 20

See all 20 drugs

Targets9

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	5	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	4	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Phase 2	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	4	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Phase 2	https://conductscience.org/library/genes/3455	Drugs and targets
ERBB2	Epidermal growth factor receptor	2	Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 2	https://conductscience.org/library/genes/2064	Drugs and targets
ERBB4	Epidermal growth factor receptor	2	Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor	Phase 2	https://conductscience.org/library/genes/2066	Drugs and targets
TYMS	Thymidylate synthase	2	Thymidylate synthase inhibitor	Phase 2	https://conductscience.org/library/genes/7298	Drugs and targets
ERBB3	Epidermal growth factor receptor	1	Epidermal growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2065	Drugs and targets
PDCD1	Programmed cell death protein 1	1	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
VDR	Vitamin D3 receptor	1	Vitamin D receptor agonist	Early phase 1	https://conductscience.org/library/genes/7421	Drugs and targets

Trials14

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00054691	ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin	Phase 2	40	2015-02-12	Skin Cancer	GEFITINIB	Its record names the disease	ClinicalTrials.gov
NCT02324608	Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer	Not applicable	15	2023-12-20	Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin	CETUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02218164	Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma	Phase 2	8	2018-07-20	Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell	CAPECITABINE, FLUOROURACIL, PEGINTERFERON ALFA-2B	Its record names the disease	ClinicalTrials.gov
NCT04163952	Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin	Phase 1	5	2024-01-18	Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma	PANITUMUMAB, TALIMOGENE LAHERPAREPVEC	Its record names the disease	ClinicalTrials.gov
NCT04234113	Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors	Phase 1	115		Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer	NANRILKEFUSP ALFA, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03291002	Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC	Phase 1	98		Melanoma (Skin), Squamous Cell Carcinoma of the Skin, Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Adenoid Cystic	CV-8102	Its record names the disease	ClinicalTrials.gov
NCT01807546	Oral Rigosertib for Squamous Cell Carcinoma	Phase 2	64		Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma, Penile Squamous Cell Carcinoma	RIGOSERTIB	Its record names the disease	ClinicalTrials.gov
NCT02883556	Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin	Phase 2	57		Carcinoma, Squamous Cell	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02268747	Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer	Phase 2	43		Skin Squamous Cell Cancer	DACOMITINIB ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT00240682	Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR	Phase 2	37		Skin Diseases, Carcinoma, Squamous Cell	CETUXIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 14

See all 14 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21810686	RESULT	1	PubMed
39904560	DERIVED	1	PubMed
36319717	DERIVED	1	PubMed
35435625	DERIVED	1	PubMed
32730186	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002529

GET https://conductscience.org/api/diseases/v1/MONDO_0002529/drugs

API reference For AI assistants